Arrowhead Pharmaceuticals market cap ARWR

Share price times shares outstanding: what the whole company sells for, since 2011.

Arrowhead Pharmaceuticals is worth $8.2B at the close on Oct 23, 2026, at $58.02 a share.

That is up 56% over the last year and up 23% over five years.

Its highest close in our data was $12.4B in Aug 2026.

Market cap over time

Year	End of year	Low	High	Change
2026 so far	$8.2B	$7.7B	$12.4B	−14%
2025	$9.5B	$1.3B	$9.5B	+304%
2024	$2.4B	$2.3B	$4.5B	−28%
2023	$3.3B	$2.5B	$4.4B	−24%
2022	$4.3B	$3.1B	$6.2B	−38%
2021	$6.9B	$6.2B	$9.4B	−12%
2020	$7.9B	$2.7B	$8.7B	+27%
2019	$6.2B	$1.2B	$7B	+464%
2018	$1.1B	$364.4M	$1.7B	+300%
2017	$275.4M	$112.9M	$323.8M	+140%
2016	$115M	$82M	$455.6M	−69%
2015	$366.3M	$306.4M	$495.4M	+3%
2014	$356.5M	$312.2M	$979.5M	−16%
2013	$422.6M	$29.6M	$422.6M	+1231%
2012	$31.8M	$23.3M	$69.7M	−28%
2011	$44.1M	$28M	$47.8M	n/a

Companies in Drug Manufacturers - General nearest Arrowhead Pharmaceuticals' size, closest first, today.

Company	Market cap
ARWRArrowhead Pharmaceuticals	$8.2B
TGTXTG Therapeutics	$8.3B
PTGXProtagonist Therapeutics	$9B
ALKSAlkermes plc.	$7.3B
CORTCorcept Therapeutics	$9.3B
AMRXAmneal Pharmaceuticals	$6.5B
BMRNBiomarin Pharmaceutical	$10.8B
LGNDLigand Pharmaceuticals	$6.1B
KNSAKiniksa Pharmaceuticals International	$6B
JAZZJazz Pharmaceuticals	$13.9B
INDVIndivior Pharmaceuticals	$4.1B
Peer median	$7.8B